Kemble George 4

What Happened

• Kemble George, a director of Sagimet Biosciences, was granted a derivative award covering 39,567 shares on June 12, 2026. The filing reports an acquisition at $0.00 per share (derivative), resulting in a reported value of $0 on the Form 4. The award is described as an option whose underlying shares will vest and become exercisable over the next 12 months.

Key Details

• Transaction date: 2026-06-12; Form 4 filed: 2026-06-15.
• Transaction type: Grant / derivative award (code A on the Form 4).
• Amount: 39,567 shares; reported price/exercise: $0.00; reported value: $0.
• Vesting: The shares underlying this option vest and become exercisable in twelve equal monthly installments following June 12, 2026, subject to continued service (see footnote F1).
• Shares owned after transaction: Not disclosed in this filing.
• Filing timeliness: Form shows the report date 2026-06-15 for a 2026-06-12 transaction; the filing does not indicate a late-filing flag in the provided record.

Context

• This was a compensatory award (an option-style derivative) rather than an open-market purchase or sale. The award vests monthly and must be exercised to convert to shares, so no immediate sale or cash transaction is implied. Such grants are common for board compensation/retention and do not by themselves indicate the director buying stock on the open market.